Q-omics provides the consensus-scored TRAJ40 profile across patient tissues and cancer cell-line models. TRAJ40 expression is associated with patient survival in 10 of 34 cancer types, with the highest sampling consensus in TGCT. Among the 18 cancer types available for tumor–normal comparison, TRAJ40 is differentially expressed in 3, with the highest sampling consensus in KIRC. Additionally, TRAJ40 RNA expression shows 12,467 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight TGCT, KIRC, and LSCC as cancer lineages where TRAJ40 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for TRAJ40 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes TRAJ40 survival associations across molecular data types. TRAJ40 RNA expression shows survival associations in the most cancer types (10). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible TRAJ40 RNA expression–survival associations across cancer types. High TRAJ40 expression shows unfavorable associations in TGCT, STAD and MESO, but favorable associations in KIRC, SKCM and BLCA. The TGCT Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify TGCT as the clearest survival context for TRAJ40 RNA expression.
This table summarizes TRAJ40 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 3. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for TRAJ40. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. TRAJ40 shows lower tumor expression in LUSC and higher tumor expression in KIRC and BRCA. The KIRC box plot shows higher TRAJ40 RNA expression in tumor versus normal tissue (log2 FC = +0.233, t-test p < 0.001).
This table shows molecular features associated with TRAJ40 in patient tissues and cancer cell lines. In patient samples, TRAJ40 shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set.
